Lurbinectedin may inhibit the proliferation and migration of bladder cancer cells and promote their death by upregulating the expression of the key pyroptosis protein GSDMD. The results of this study indicate that Lurbinectedin has the potential to be developed into an ideal therapeutic drug for bladder cancer.